Charles River Laboratories International (NYSE:CRL) Reaches New 12-Month High – Still a Buy?

by · The Markets Daily

Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $228.88 and last traded at $225.56, with a volume of 153606 shares changing hands. The stock had previously closed at $218.82.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. William Blair upgraded shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a report on Monday, October 6th. Argus set a $200.00 price objective on Charles River Laboratories International in a research note on Monday, November 17th. Wall Street Zen upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating in a report on Sunday, December 21st. JPMorgan Chase & Co. increased their price target on Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a report on Monday, December 15th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Charles River Laboratories International in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Charles River Laboratories International has a consensus rating of “Moderate Buy” and a consensus target price of $203.07.

Read Our Latest Research Report on CRL

Charles River Laboratories International Stock Up 2.3%

The stock’s fifty day moving average price is $187.95 and its 200-day moving average price is $172.39. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $11.01 billion, a price-to-earnings ratio of -143.58, a P/E/G ratio of 6.60 and a beta of 1.61.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last released its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, beating analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $990.43 million. During the same quarter last year, the firm earned $2.59 earnings per share. The firm’s revenue for the quarter was down .5% compared to the same quarter last year. On average, sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CRL. Cromwell Holdings LLC increased its position in shares of Charles River Laboratories International by 542.9% during the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock worth $27,000 after purchasing an additional 152 shares during the last quarter. Neo Ivy Capital Management bought a new position in shares of Charles River Laboratories International in the second quarter valued at $29,000. Rothschild Investment LLC increased its holdings in Charles River Laboratories International by 82.4% during the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after buying an additional 84 shares during the last quarter. Atlantic Union Bankshares Corp bought a new stake in Charles River Laboratories International during the third quarter worth $31,000. Finally, Geneos Wealth Management Inc. lifted its stake in Charles River Laboratories International by 98.0% in the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 145 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

About Charles River Laboratories International

(Get Free Report)

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

Further Reading